Siemens Healthineers: Credit Suisse reiterates 'outperform'
(CercleFinance.com) - Credit Suisse on Friday reiterated its "outperform" rating on the Siemens Healthineers share, seeing the German health technology company as an "attractive" growth story.
The broker said the medium-term outlook relating to the company's imaging business outweigh short-term headwinds regarding its diagnostics unit.
"The key driver of this is the structural growth trends in imaging supported by emerging market penetration and an aged European installed base," it wrote in a note.
Credit Suisse said it would recommend investors use any near-term share price weakness driven by soft diagnostic volumes as buy opportunities, given that imaging appears to be resisting pretty well.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The broker said the medium-term outlook relating to the company's imaging business outweigh short-term headwinds regarding its diagnostics unit.
"The key driver of this is the structural growth trends in imaging supported by emerging market penetration and an aged European installed base," it wrote in a note.
Credit Suisse said it would recommend investors use any near-term share price weakness driven by soft diagnostic volumes as buy opportunities, given that imaging appears to be resisting pretty well.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.